Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07207941

Effect of Probiotics on Quality of Life, Activities of Daily Living and Anxiety in Post Stroke Patients

Research on Effect of probiotics on quality of life, activities of daily living and anxiety in post stroke patients

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National University of Malaysia

Kuala Lumpur, 56000, Malaysia

Location contact

Hui Jan Tan, MD FRCP MMed

CONTACT

[email protected]

0391455555 ext. 5583

Hui Jan Tan, MD FRCP MMed

PRINCIPAL_INVESTIGATOR

Nasir Shafiee, Masters in Obs and Gyne

CONTACT

[email protected]

0391455555

About this study

Background:

Stroke survivors often experience reduced quality of life (QoL), impaired activities of daily living (ADL), and high levels of anxiety. Emerging evidence suggests that modulation of the gut-brain axis through probiotics may improve neuropsychological and functional outcomes. However, data from Malaysian populations are lacking.

Objective:

To evaluate the effects of probiotic supplementation compared to placebo on QoL, ADL, anxiety symptoms, and functional outcomes in post-stroke patients.

Study Design:

This is a single-center, randomized, double-blind, placebo-controlled clinical trial.

Methods:

A total of 110 patients with moderate ischemic stroke (mRS 2-4) within 3 months of onset will be recruited from the Neurology Clinic, Hospital Canselor Tuanku Muhriz, Kuala Lumpur. Participants will be randomized (1:1) to receive either:

  • Intervention: HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.
  • Control: Matching placebo sachets, identical in appearance and schedule. Both groups will continue standard stroke treatment. Primary outcome is QoL measured using the Stroke-Specific Quality of Life (SS-QoL) scale. Secondary outcomes include ADL (Barthel Index), anxiety symptoms (GAD-7), and functional status (mRS score). Assessments will be performed at baseline and 3 months.

Sample Size:

A total of 110 patients (55 per arm) will provide sufficient power to detect clinically meaningful differences, accounting for a 5% dropout rate.

Data Analysis:

Intention-to-treat analysis will be conducted using SPSS v26. Between-group differences will be assessed using appropriate parametric or non-parametric tests, with significance set at p < 0.05.

Study Duration:

Recruitment will begin in Sept 2025 and is expected to complete by May 2028.

Expected Impact:

This study will provide new evidence on the role of probiotics in improving QoL, daily functioning, and psychological well-being among Malaysian post-stroke patients, potentially informing adjunctive rehabilitation strategies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with moderate ischemic stroke with mRS score of 2-4 from onset of stroke up to 3 months.
  • Patients aged 18 to 80 years, who are able to read and write in English and/or Bahasa Malaysia
  • Provide informed consent

Exclusion criteria

  • Patients with aphasia
  • Patients who have received thrombolysis or mechanical thrombectomy
  • Gastrointestinal related diseases such as lactose intolerance, coeliac disease, Renal or hepatic insufficiency (Based on recent six-month blood profile)
  • Progressive neurological disease (Alzheimer's disease, Parkinson's Disease, Motor Neuron Disease)
  • Pregnancy and breastfeeding.
  • Secondary cause of stroke- vasculitis, cerebral venous sinus thrombosis, connective tissue disorders
  • Past history of psychiatric disorders (depression, anxiety)
  • Recent use of probiotics and allergies to probiotics
  • Immunosuppressed patients (HIV, malignancy)
  • Patient with septicemia

Treatment and study plan

Hexbio

Dietary Supplement

HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.

Placebo

Other

Matching placebo sachets, identical in appearance and schedule

Primary outcomes

  1. Primary Objective

    Time frame: 3 months

    QoL measured using the Stroke-Specific Quality of Life (SS-QoL) scale. To assess the patient's quality of life, validated Stroke Specific Quality of life (SS-QoL) questionnaire in English version will be used. This questionnaire consists of 12 domains which includes energy, family roles, language, mobility, mood, personality, self-care, social roles, thinking, upper extremity function, vision, and work/productivity. Each question is scored using 5 point Likert scale and the total score is calculated which can range from 49-245. The higher the score, better the quality of life. This questionnaire is validated and requested for permission.

Secondary outcomes

  1. Secondary objectives: Activities of daily living

    Time frame: 3 months

    Activities of daily living is measured using Barthel Index (BI) which contains of 10 items. BI is a measurement scale used to assess an individual's ability to perform activities of daily living (ADL) and mobility. The score ranges from 0-10 and the overall score is calculated. The higher the score, better the functional status.

  2. Secondary objective: Anxiety Score

    Time frame: 3 months

    Anxiety score is calculated using Generalised Anxiety Disorder- 7 (GAD-7) score. GAD 7 is a screening tool and it has 7 items with score ranging from 0-3 for each item and the total score is calculated. The higher the score, the worse the anxiety symptoms. A score of 10 indicates anxiety.

  3. Secondary objective: modified Rankin scale

    Time frame: 3 months

    Modified Rankin Scale (mRS) assess functional recovery and independence after stroke. It uses a 5 point scale, where a higher scale indicates more severe disability.

Study contacts

Contact information is provided by the study sponsor or research team.

Hui Jan Tan, MD FRCP MMed

CONTACT

[email protected]

+60391455555 ext. 5583

Sponsors and collaborators

Lead sponsor

National University of Malaysia

Other

Collaborators

  • B-Crobes Laboratory Sdn. Bhd

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2028
First posted
Oct 6, 2025
Registry last updated
Oct 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.